{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:46:41Z","timestamp":1791884801053,"version":"4.3.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess the efficacy of topical insulin for the treatment of various ocular surface diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective, multicenter cohort study was conducted at the university hospitals of Brussels and Ghent and included 57 eyes (45 patients) treated with topical insulin (1 IU\/mL 4 times daily) for neurotrophic keratopathy (NK) (n = 31), dry eye disease (DED) (n = 9), graft-versus-host disease (GVHD) (n = 7), and various other ocular surface diseases (n = 10) between October 2023 and March 2025. Data from medical records and anterior segment photographs were analyzed. Primary outcome was treatment success; secondary outcomes included clinical evolution, symptoms, data on persistent epithelial defects (PED), vision, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Treatment success was highest in NK eyes (83.9%) as compared to DED and GVHD eyes (44.4% and 14.3%, respectively), with a statistically significant difference between NK and GVHD (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.028). Treatment success did not differ significantly between eyes with NK grade 1, 2, and 3 (83.3%, 72.7%, and 92.9%, respectively) (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). Twenty out of 28 (71.4%) PED eyes of various etiologies achieved complete closure after 5.2 weeks, whereas 6 eyes (21.4%) showed partial closure, and 2 eyes (7.1%) showed no improvement. One eye showed a significant transient IOP increase; no other adverse events were noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results suggest that topical insulin drops are a safe and affordable treatment option for ocular surface diseases, particularly for NK eyes with and without PED. Further prospective clinical trials, however, are needed to confirm the efficacy and define the place of topical insulin in standardized treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ico.0000000000004331","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:01:29Z","timestamp":1791882089000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Topical Insulin in the Treatment of Ocular Surface Disease: A Retrospective Cohort Study"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1142-1881","authenticated-orcid":false,"given":"Marie","family":"Lammens","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Universitair Ziekenhuis Brussel (UZB), Jette, Belgium;"},{"name":"Neuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences (C4N), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Roels","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ghent University Hospital (UZG) Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Oellerich","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Universitair Ziekenhuis Brussel (UZB), Jette, Belgium;"},{"name":"Neuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences (C4N), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1115-7834","authenticated-orcid":false,"given":"Sorcha","family":"N\u00ed Dhubhghaill","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Universitair Ziekenhuis Brussel (UZB), Jette, Belgium;"},{"name":"Neuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences (C4N), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Krolo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Universitair Ziekenhuis Brussel (UZB), Jette, Belgium;"},{"name":"Neuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences (C4N), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"R2-20261013","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/07853890.2022.2045035","article-title":"Neurotrophic keratopathy: current challenges and future prospects","volume":"54","author":"NaPier","year":"2022","journal-title":"Ann Med"},{"key":"R3-20261013","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/bjo.29.7.361","article-title":"The use of insulin in the treatment of corneal ulcers","volume":"29","author":"Aynsley","year":"1945","journal-title":"Br J Ophthalmol"},{"key":"R4-20261013","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/ICO.0000000000003877","article-title":"Drug repurposing for corneal diseases-should we look back more often to move forward?","volume":"44","author":"Oellerich","year":"2025","journal-title":"Cornea"},{"key":"R5-20261013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/joco.joco_32_24","article-title":"Topical insulin for neurotrophic-related epithelial defects: where do we stand? A systematic review","volume":"36","author":"Wouters","year":"2024","journal-title":"J Curr Ophthalmol"},{"key":"R6-20261013","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/jop.2024.0016","article-title":"Topical insulin for ocular surface disease","volume":"40","author":"Cid-Bertomeu","year":"2024","journal-title":"J Ocul Pharmacol Ther"},{"key":"R7-20261013","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.survophthal.2024.04.003","article-title":"The role of topical insulin in ocular surface restoration: a review","volume":"69","author":"Krolo","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"R8-20261013","first-page":"e62065","article-title":"The utilization of topical insulin for ocular surface diseases: a narrative review","volume":"16","author":"Moin","year":"2024","journal-title":"Cureus"},{"key":"R9-20261013","doi-asserted-by":"crossref","first-page":"102127","DOI":"10.1016\/j.ajoc.2024.102127","article-title":"Topical insulin to treat a conjunctival defect after glaucoma surgery: a case report","volume":"36","author":"Burgos-Blasco","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R10-20261013","first-page":"963","article-title":"Identification of insulin in the tear film and insulin receptor and IGF-1 receptor on the human ocular surface","volume":"43","author":"Rocha","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20261013","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.4103\/IJO.IJO_2935_24","article-title":"Management of refractory persistent epithelial defect treatment with topical insulin: an Indian pilot study","volume":"73","author":"Jain","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"R12-20261013","doi-asserted-by":"crossref","first-page":"12459","DOI":"10.1038\/s41598-024-63091-y","article-title":"Topical insulin for refractory persistent corneal epithelial defects","volume":"14","author":"Abdi","year":"2024","journal-title":"Sci Rep"},{"key":"R13-20261013","doi-asserted-by":"crossref","first-page":"397","DOI":"10.18502\/jovr.v19i4.13977","article-title":"Long-term results of topical insulin treatment for persistent corneal epithelial defects","volume":"19","author":"Almeida","year":"2024","journal-title":"J Ophthalmic Vis Res"},{"key":"R14-20261013","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1177\/1120672120958307","article-title":"Topical insulin for refractory persistent corneal epithelial defects","volume":"31","author":"Diaz-Valle","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R15-20261013","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1111\/aos.14997","article-title":"Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea","volume":"100","author":"Diaz-Valle","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"R16-20261013","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/ICO.0000000000001297","article-title":"Use of topical insulin to treat refractory neurotrophic corneal ulcers","volume":"36","author":"Wang","year":"2017","journal-title":"Cornea"},{"key":"R17-20261013","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/11206721231206790","article-title":"Topical insulin, a novel corneal epithelial regeneration agent in dry eye disease","volume":"34","author":"Burgos-Blasco","year":"2024","journal-title":"Eur J Ophthalmol"},{"key":"R18-20261013","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archopht.125.8.1082","article-title":"Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus","volume":"125","author":"Zagon","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R19-20261013","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/ICO.0000000000002858","article-title":"Topical insulin-utility and results in refractory neurotrophic keratopathy in stages 2 and 3","volume":"41","author":"Soares","year":"2022","journal-title":"Cornea"},{"key":"R20-20261013","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jcjo.2025.11.009","article-title":"Real-world effectiveness of topical insulin for neurotrophic keratopathy: retrospective case series of 29 eyes","volume":"61","author":"Padda","year":"2026","journal-title":"Can J Ophthalmol"},{"key":"R21-20261013","doi-asserted-by":"crossref","first-page":"102227","DOI":"10.1016\/j.ajoc.2024.102227","article-title":"Topical insulin used alone or in combination with drug-depository contact lens for refractory cases of neurotrophic keratopathy","volume":"36","author":"Mancini","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R22-20261013","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.2147\/OPTH.S561775","article-title":"Comparison of amniotic membrane extract and insulin eye drops for the management of persistent epithelial defects: a multicenter retrospective study","volume":"19","author":"Buzzi","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R23-20261013","doi-asserted-by":"crossref","first-page":"10986","DOI":"10.1038\/s41598-024-60699-y","article-title":"Topical insulin in neurotrophic keratopathy after diabetic vitrectomy","volume":"14","author":"Eleiwa","year":"2024","journal-title":"Sci Rep"},{"key":"R24-20261013","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/ICO.0000000000003145","article-title":"Healing of chemical injury-related persistent corneal epithelial defects with topical insulin","volume":"42","author":"Balal","year":"2023","journal-title":"Cornea"},{"issue":"suppl 1","key":"R25-20261013","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/ICL.0000000000000623","article-title":"Short-term results of trial of topical insulin for treatment of dry eyes in diabetics","volume":"46","author":"Aniah Azmi","year":"2020","journal-title":"Eye Contact Lens"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:01:32Z","timestamp":1791882092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000004331","relation":{},"ISSN":["0277-3740","1536-4798"],"issn-type":[{"value":"0277-3740","type":"print"},{"value":"1536-4798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2026-05-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}